CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

ecopipam

Small moleculeexperimental

Ecopipam is a dopamine antagonist which is under development for the treatment of Lesch–Nyhan syndrome, Tourette syndrome, speech disorders, and restless legs syndrome. It is taken by mouth. — Wikipedia

Clinical trial activity

21 trials · 22 clinical orgs · 0 marketing orgs

Phase 1
11
Phase 2
10
Phase 3
4
Phase 4
0

Earliest trial started Feb 1, 2010 (NCT01065558)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2012

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CN1CCc2cc(Cl)c(O)cc2[C@H]2c3ccccc3CC[C@@H]21.Cl
Mol. weight
350.29 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 5h-benzo(d)naphth(2,1-b)azepin-12-ol, 11-chloro-6,6a,7,8,9,13b-hexahydro-7-methyl-, trans-(-)-
  • 6,7,7a,8,9,13b-hexahydro-3-chloro-2-hydroxy-n-methyl-5h-benzo(d)naphtho-(2,1b)azepine
  • ecopipam
  • ecopipam
  • ecopipam
  • ecopipam
  • ecopipam
  • sch39166
  • sch 39166
  • sch-39166
  • sch-39166
  • sch-39166

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06669091Phase 1Nov 5, 2024Emalex Biosciences
NCT06194864Phase 1Jan 18, 2024Cambridge Cognition Ltd, Emalex Biosciences, Syneos Health
NCT06021522Phase 3Aug 16, 2023Emalex Biosciences
NCT05841160Phase 1Mar 15, 2023Emalex Biosciences, PPD
NCT05615220Phase 3Dec 31, 2022Emalex Biosciences
NCT05334108Phase 1Apr 26, 2022Emalex Biosciences, ICON, Nuventra Pharma Sciences, Inc.
NCT04902105Phase 1May 13, 2021Emalex Biosciences, Nuventra Pharma Sciences, Inc., Syneos Health
NCT04881955Phase 1May 12, 2021Covance, Emalex Biosciences
NCT04764851Phase 1Feb 18, 2021Emalex Biosciences, Nuventra Pharma Sciences, Inc., Syneos Health
NCT04492956Phase 2Oct 2, 2020Emalex Biosciences, Premier Research Group, University of California, Riverside
NCT04114539Phase 2Oct 31, 2019Emalex Biosciences
NCT04007991Phase 2Jun 20, 2019Emalex Biosciences
NCT03218969Phase 1/Phase 2 (Phase 2)Sep 18, 2017Methodist Cancer Center, Houston, Texas, Restless Legs Syndrome Foundation
NCT02909088Phase 2/Phase 3 (Phase 3)Sep 1, 2016CITrials, Gerald Maguire, MD, University of California, Riverside
NCT02102698Phase 2Mar 1, 2014Psyadon Pharma, University of Cincinnati
NCT01751802Phase 3Dec 1, 2012Emory University, Psyadon Pharma
NCT01408394Phase 1Aug 1, 2011Psyadon Pharma, Shin Nippon Biomedical Laboratories
NCT01215357Phase 2Oct 1, 2010Psyadon Pharma, University of California, Los Angeles, University of Iowa, University of Minnesota, Yale University
NCT01244633Phase 1/Phase 2 (Phase 2)Oct 1, 2010Psyadon Pharma, University of Cincinnati
NCT01065558Phase 1Feb 1, 2010Emory University, Psyadon Pharma, University of California, San Diego
Showing 20 of 21 trials
Page 1 / 2

Organizations

Research & Development (22)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Emalex BiosciencesFor profit131342019
Psyadon PharmaFor profit6632010
Nuventra Pharma Sciences, Inc.For profit3012021
Syneos HealthFor profit3012021
Emory UniversityAcademic/Hospital2022010
University of California, RiversideAcademic/Hospital2022016
University of CincinnatiAcademic/Hospital2012010
Cambridge Cognition LtdFor profit1012024
CITrialsFor profit1012016
CovanceFor profit1012021
Gerald Maguire, MDAcademic/Hospital1112016
ICONFor profit1012022
Methodist Cancer Center, Houston, TexasAcademic/Hospital1112017
PPDFor profit1012023
Premier Research GroupFor profit1012020
Restless Legs Syndrome FoundationAcademic/Hospital1012017
Shin Nippon Biomedical LaboratoriesFor profit1012011
University of California, Los AngelesAcademic/Hospital1012010
University of California, San DiegoAcademic/Hospital1012010
University of IowaAcademic/Hospital1012010
22 organizations
Page 1 / 2